Sec Form 4 Filing - Klein Lawrence Otto @ CRISPR Therapeutics AG - 2021-03-23

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Klein Lawrence Otto 2. Issuer Name and Ticker or Trading Symbol CRISPR Therapeutics AG [ CRSP] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) CBO & COO (Last) (First) (Middle) C/O CRISPR THERAPEUTICS, INC., 610 MAIN STREET 3. Date of Earliest Transaction (MM/DD/YY) 03/23/2021 (Street) CAMBRIDGE, MA02139 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Shares 03/23/2021 M 12,000 A $ 44.67 25,050 D Common Shares 03/23/2021 M 22,000 A $ 51.49 47,050 D Common Shares 03/23/2021 M 10,000 A $ 29.87 57,050 D Common Shares 03/23/2021 M 20,000 A $ 40.87 77,050 D Common Shares 03/23/2021 M 12,000 A $ 14.43 89,050 D Common Shares 03/23/2021 M 12,000 A $ 17.66 101,050 D Common Shares 03/23/2021 S( 1 ) 88,000 D $ 128.2 ( 2 ) 13,050 D Common Shares 03/23/2021 S( 1 ) 12,000 D $ 126.97 ( 3 ) 1,050 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option (Right to Buy) $ 14.43 03/23/2021 M 12,000 ( 4 ) 06/14/2027 Common Shares 12,000 $ 0 2,666 D Stock Option (Right to Buy) $ 17.66 03/23/2021 M 12,000 ( 5 ) 11/14/2027 Common Shares 12,000 $ 0 3,000 D Stock Option (Right to Buy) $ 51.49 03/23/2021 M 22,000 ( 6 ) 03/06/2028 Common Shares 22,000 $ 0 38,000 D Stock Option (Right to Buy) $ 29.87 03/23/2021 M 10,000 ( 7 ) 01/01/2029 Common Shares 10,000 $ 0 10,000 D Stock Option (Right to Buy) $ 40.87 03/23/2021 M 20,000 ( 8 ) 03/05/2029 Common Shares 20,000 $ 0 25,000 D Stock Option (Right to Buy) $ 44.67 03/23/2021 M 12,000 ( 9 ) 03/10/2030 Common Shares 12,000 $ 0 43,000 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Klein Lawrence Otto C/O CRISPR THERAPEUTICS, INC. 610 MAIN STREET CAMBRIDGE, MA02139 CBO & COO Signatures /s/ Michael Esposito, attorney-in-fact 03/25/2021 Signature of Reporting Person Date

Explanation of Responses:

( 1 )The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. ( 2 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.78 to $132.255, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. ( 3 )The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.80 to $130.015, inclusive. The reporting person undertakes to provide to the Issuer, any security hol der of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. ( 4 )100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on July 15, 2017. ( 5 )100% of the shares shall vest in 48 equal monthly installments on the fifteenth day of each month, with the first vesting event on December 15, 2017. ( 6 )100% of the shares shall vest in 48 equal monthly installments on the seventh day of each month, with the first vesting event on April 7, 2018. ( 7 )25% of the option shall vest on January 2, 2020, and the remaining 75% of the shares shall vest in 36 equal monthly installments on the final day of each month. ( 8 )This option was granted on March 5, 2019 with respect to 45,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. ( 9 )This option was granted on March 10, 2020 with respect to 55,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.